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Phosphorylation of zinc channel ZIP7 drives
MAPK, PI3K and mTOR growth and proliferation
signalling†
T. Nimmanon,‡ab S. Ziliotto,‡a S. Morris,a L. Flanagana and K. M. Taylor*a
Zinc is an essential trace element participating in diverse biological processes. Cellular zinc levels are
strictly controlled by two families of transport proteins: ZIP channels (SLC39A) and ZnT transporters
(SLC30A). ZIP channels increase cytosolic zinc levels by importing zinc into cells or releasing zinc
from intracellular stores such as the ER. Among all the 14 human members of the ZIP family, ZIP7 is a
gatekeeper of zinc release from intracellular stores, requiring post-translational activation by phosphoryl-
ation on residues S275 and S276, resulting in activation of multiple downstream pathways. Employing
site-directed mutagenesis, we investigated the importance of these individual serine residues as well
as other predicted phosphorylation sites on ZIP7, showing that all four sites are required for maximal
ZIP7 activation. Using phosphor-protein arrays, we also discovered the major signalling pathways that
were activated as a direct result of ZIP7-mediated zinc release from intracellular stores. These data
reveal the role of ZIP7-mediated zinc release from intracellular stores in driving major pathways, such as
MAPK, mTOR and PI3K-AKT, involved in providing cell survival and proliferation and often over activated
in cancer.
Significance to metallomics
We have previously discovered that zinc transporter ZIP7-mediated zinc release from stores is central to zinc acting as a second messenger and activating
numerous signalling pathways known to be important in health and disease. Having explored further the role of ZIP7 phosphorylation and the particular
signalling pathways activated by ZIP7-mediated zinc release, we reveal activation of key pathways involved in driving cell survival and proliferation. This
discovery together with our new phospho-ZIP7 antibody has increased our understanding of the role of intracellular zinc in maintaining cell growth and
provided a new tool to examine active zinc release in biological systems.
A Introduction
Zinc is the second most abundant trace element in the human
body after iron. Zinc is involved in a vast variety of biological
processes, being essentially required for the immune system,1 the
anti-oxidant mechanism,2 and neurotransmission.3 Importantly,
zinc has been shown to act as a second messenger in diﬀerent
cell types, including mast cells4 and breast cancer cells.5 As such,
when a cell is activated by an extracellular stimulus, zinc is
released from intracellular stores, such as the ER, resulting in
activation of diﬀerent tyrosine kinase pathways through the
inhibitory action of zinc on protein tyrosine phosphatases.6
The intracellular level of zinc is tightly controlled by two
families of zinc transport proteins: ZIP channels (Zrt- and
Irt-like proteins, zinc importers, or SLC39A) and ZnT transporters
(zinc exporter or SLC30A).7 ZIP channels increase the cytosolic
zinc level by mobilising zinc from the extracellular space or
intracellular stores, whereas ZnT transporters facilitate zinc
transport in the opposite direction.8 ZIP channels are divided
into 4 subfamilies: gufA (ZIP11), subfamily I (ZIP9), subfamily II
(ZIP1–3), and the LIV-1 subfamily (ZIP4–8, 10, and 12–14).9
In contrast to other LIV-1 subfamily members, ZIP7 is located on
the endoplasmic reticulummembrane and is post-translationally
regulated by CK2-mediated phosphorylation on residues S275
and S276.5 This ZIP7 phosphorylation results in zinc release from
intracellular stores,5 which activates multiple tyrosine kinases as
well as ERK1/2 and AKT.10 Importantly, some of these kinases
such as EGFR,11 IGF-1R,12 and Src13 promote the aggressive
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behaviour of breast cancer cells that have acquired tamoxifen
resistance.14 Furthermore, the increased activation of these
kinases in these tamoxifen-resistant cells has been attributed to
increased activation of ZIP7 and the subsequent higher level of
intracellular zinc,10 linking ZIP7 to the mechanism of acquiring
tamoxifen resistance in breast cancer.15 Additionally, given
the ubiquitous expression of ZIP7 in the human body,16 its
location on ER zinc stores,16,17 and its activation mechanism by
phosphorylation,5 ZIP7 has been suitably designated as ‘‘a hub
for tyrosine kinase activation’’.18
In light of this information, we developed a monoclonal
antibody that recognises ZIP7 specifically when phosphorylated
on residues S275 and S276 and are using this to determine the
downstream targets of ZIP7-mediated zinc release. Upon cellular
exposure to an external stimulus, ZIP7 is activated by phosphoryl-
ation within 2 minutes, and AKT is activated within 5 minutes in
ZIP7-transfected MCF-7 cells.5 In this present study, we charac-
terise this new pZIP7 antibody to confirm it recognises the
phosphorylated form of ZIP7 and assess its usefulness to detect
ZIP7 activation in cells. Employing this antibody, we next deter-
mine the importance of the individual residues S275 and S276, as
well as other potential recently discovered phosphorylation sites,
S293 and T294, in ZIP7 function, revealing that all four residues
are required for maximal activation of ZIP7. Furthermore, we
investigate the multiple kinases phosphorylated downstream of
ZIP7-mediated zinc release, employing three diﬀerent types of
phospho-protein antibody arrays, confirming activation of three
major signalling pathways, MAPK, PI3K-AKT and mTOR, as the
major downstream targets of ZIP7. This data reveals new down-
stream targets of ZIP7-mediated zinc release and explains its role
in driving cell proliferation and survival.
B Materials and methods
Cell preparation, treatment and transfection
MCF-7 cells were cultured as previously described.10 Treatments
used were 20 mM zinc plus 10 mM sodium pyrithione (zinc
ionophore, Sigma-Aldrich, H3261) and 10 ng ml1 EGF and
500 nM ionomycin (calcium ionophore, Sigma-Aldrich, I3909).
The generation of SLC39A7 in a pcDNA3.1/V5-His-TOPO vector
has been described.16 Site-directed mutagenesis was performed
to create ZIP7 mutants (S275D/S276D, S275A, S276A, S293A, and
T294A), and confirmed by sequencing (Fig. S1A, ESI†). The ZIP7
S275A/S276A mutant has previously been described.5 Cells were
transfected with Lipofectamine-2000 (Life Technologies) according
to the manufacturer’s instruction. Briefly, cells grown on 35 mm
dishes with 70–90% confluence were transfected with 3.5 mg of
DNA and 27.5 ml of the reagent in the antibiotic-free medium.
Robust transfection of the mutants was confirmed using V5
immunofluorescence (Fig. S1B, ESI†).
Antibodies
Rabbit total ZIP710 and mouse monoclonal pZIP7 (S275/S276,
Merck, MABS 1262) antibodies have been developed in house.
Other antibodies used were pAKT (S473, rabbit, 9271), pGSK-3b
(S9, rabbit, 9336), pCREB (S133, rabbit, 9198), p-p38 MAPK
(Y180/Y182, rabbit), p-p70 S6 (T421/S424, rabbit, 9204), and
pWNK1 (T60, rabbit, 4946) antibodies from Cell Signaling
Technology; p-p53 (S392, rabbit, SAB4503954) and b-actin (A5316)
antibodies from Sigma-Aldrich; V5 (rabbit, SC-83849-R), and
pSTAT5 (S726, rabbit, SC-12893) from Santa Cruz Biotechnology;
V5 (mouse, 46-0705) from Invitrogen; and V5 (rabbit, Ab9116)
from Abcam.
Fluorescent microscopy and FACS analysis
1  105 cells were grown on 0.17 mm thick coverslips for
5–7 days prior to transfection. Coverslips were fixed and processed
as previously described.19 Antibodies used for immunofluores-
cence were pZIP7 (1/200) and V5 (1/1000). For FACS analysis
using BD FACSVerse, cells were loaded with 5 mM Fluozin-3AM
(Invitrogen) for 30 min at 37 1C, followed by 30 min recovery
in medium. FACS data were analysed using Flowing Software
version 2.50 (Turku Centre for Biotechnology).
Blotting, immunoprecipitation and arrays
Cells were harvested, washed with PBS, lysed for 1 hour at 4 1C
with lysis buﬀer pH7.6 (50 mM Tris, 150 mM NaCl, 5 mM EGTA
and 1% Triton X-100) with a protease inhibitor cocktail for
mammalian cells (Sigma-Aldrich, P8340) and phosphatase inhi-
bitors (2 mM sodium orthovanadate and 50mM sodium fluoride).
Western blotting results of 20 mg per lane from three separate
experiments were normalised to b-actin values. All primary anti-
bodies were used at a 1/1000 dilution. Antibody arrays used were
the human phospho-RTK (ARY001B), phospho-kinase (ARY003B),
and phospho-MAPK (ARY002B) arrays from R&D Systems. Each
membrane was applied with 300 mg cell lysate according to
manufacturer’s instructions. Signal intensities were determined
by densitometric analysis using Alpha DigiDoc version 4.10. Heat
maps were generated using a GENE-E matrix visualization and
analysis platform (The Broad Institute).
Statistics
Statistical analysis was performed using either Student’s t-test or
ANOVA with Post-hoc Dunnett tests. Significance was assumed
with * = po 0.05, * = po 0.01, and *** = po 0.001. Error bars
are standard errors from at least three diﬀerent experiments.
C Results
The pZIP7 antibody recognises phosphorylated and
activated ZIP7
We have developed a pZIP7 antibody (Fig. S1C, ESI†) to recognise
ZIP7 specifically when phosphorylated on residues S275 and
S276, a modification of ZIP7 that triggers the zinc transport
function of ZIP7.5 Western blotting was performed and results
obtained with pZIP7 and total ZIP7 antibodies were compared.
The total ZIP7 antibody recognised protein bands at 40 kDa and
35 kDa (Fig. 1A). In contrast to the total ZIP7 antibody, the pZIP7
antibody recognised a band at 48 kDa (Fig. 1A), consistent with a
mobility shift due to phosphorylation. We examined the protein
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sequence of ZIP7 for any additional potential phosphorylation sites
and found four potential sites according to mass spectrometry-
based proteomic studies: S275, S276, S293, and T294 (Table 1).
We next confirmed previous observations that zinc treatment
of ZIP7-transfected cells increases ZIP7-mediated zinc release
within 5 minutes as judged by AKT activation5 (Fig. 1B) and that
the pZIP7/ZIP7 ratio (Fig. 1C) or the pZIP7 levels normalised to
b-actin (Fig. 1D) increased from 2 minutes, consistent with ZIP7
serine phosphorylation prior to activation of AKT.5 In contrast,
cells transfected with the ZIP7 S275A/S276A mutant showed no
activation of pZIP7 after zinc treatment (Fig. 1D).
To determine the specificity of this antibody for activated
ZIP7, immunofluorescence was performed on cells transfected
with either ZIP7 wild-type or ZIP7 S275A/S276A (phosphoablative)
and S275D/S276D (phosphomimetic) mutants, which contain a
C-terminal V5 tag. Forty percent of cells transfected with wild-type
Fig. 1 Recognition of ZIP7 activation by the pZIP7 (S275/S276) antibody. (A) Immunoblotting in MCF-7 cells using the pS275/S276 ZIP7 antibody detects
a band at 48 kDa, compared to bands of 40 and 35 kDa for the total ZIP7 antibody. (B) Immunoblotting of pS473 AKT in MCF-7 cells transfected with
wild-type ZIP7 demonstrates AKT activation after 5 minutes of zinc treatment. (C) Immunoblotting in MCF-7 cells transfected with wild-type ZIP7 shows a
pS275 S276 ZIP7 (48 kDa) to total ZIP7 (35 kDa) ratio demonstrating ZIP7 phosphorylation after 2 minutes of zinc treatment. (D) Immunoblotting using the
pS275/S276 ZIP7 antibody demonstrates ZIP7 phosphorylation on residues S275 and S276 (48 kDa) after 2 minutes of zinc treatment in MCF-7 cells
transfected with wild-type ZIP7, in contrast to cells transfected with the ZIP7 S275A/S276A mutant. (E) Immunostaining using V5 and pS275/S276 ZIP7
antibodies, which were conjugated to alexa fluor 488 (green) and 594 (red), respectively, reveals that the pZIP7 antibody recognises 40% cells transfected
with ZIP7 wild-type, 100% cells transfected with ZIP7 S275D/S276D, and 0% cells transfected with ZIP7 S275A/S276A mutants. Statistical significance is
compared to time 0. * = p o 0.05, ** = p o 0.01, and *** = p o 0.001. Scale bar, 12 mm.
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ZIP7 stained positive for pZIP7 (Fig. 1E) compared to 0% when
transfected with the ZIP7 S275A/S276A mutant, demonstrating
that the antibody only recognised these residues when they were
phosphorylated. In contrast, almost 100% of cells transfected with
the ZIP7 S275D/S276D mutant stained positive for pZIP7 (Fig. 1E).
These findings confirm that the pZIP7 antibody recognises ZIP7
only when residues S275 and S276 are phosphorylated.
S275, S276, S293, and T294 are required for ZIP7 maximal
activation
To investigate whether the individual residues S275, S276, S293,
and T294 were required for ZIP7 activation, cells were transfected
with appropriate mutants and tested for their ability to initiate
a ZIP7-mediated zinc release. Cells transfected with these ZIP7
mutants required 10 minutes after zinc treatment in order to
activate AKT (Fig. 2A and B), in contrast to cells transfected with
wild-type ZIP7, which were able to activate AKT within 5 minutes
after zinc treatment5 (Fig. 1B), suggesting that all these residues
were required for the maximal activation of ZIP7. Furthermore,
the ZIP7 S293A and T294A mutants did not appear to activate
ZIP7 during the 15 minutes of zinc treatment (Fig. 2A and C),
suggesting that residues S293 and T294 may play a role in ZIP7
activation. However, both these mutants had increased ZIP7
phosphorylation before any zinc treatment (Fig. 2A) when com-
pared to the wild type ZIP7 (Fig. 1C and D), which may be
suggestive of an inhibitory role of S293 and T294 in the initiation
of ZIP7 phosphorylation on residues S275 and S276. This needs
further examination.
Investigating downstream targets of ZIP7-mediated zinc release
We have previously reported the ability of CK2-mediated ZIP7
activation of zinc release from cellular stores to activate phos-
phorylation of tyrosine kinases.5,10 To further identify additional
kinases that are phosphorylated as a result of ZIP7-mediated zinc
release from cellular stores, we employed 3 diﬀerent antibody
arrays: the phospho-RTK, phospho-kinase, and phospho-MAPK
arrays, which are able to indicate phosphorylation of up to
49 RTKs, 43 kinases, and 26 MAPKs, respectively. We tested these
arrays with MCF-7 cells with or without transfection with wild-
type ZIP7 and with or without zinc treatment for 10 minutes.
Given that endogenous ZIP7 activates AKT within 10 minutes
of zinc treatment (Fig. 1D), we performed zinc treatment for
10 minutes to allow suﬃcient time for ZIP7-mediated zinc
release and downstream activation of zinc-stimulated eﬀectors,
with limited activation of the additional downstream pathways.
To highlight the key kinases that were activated, only those with
changes in density more than 10 000 units are indicated on the
arrays with bar graphs also shown (Fig. 3A–C). Changes in the
signal intensities of all the activated kinases are also presented
as heat maps (Fig. 4A–C) and bar graphs (Fig. S2, ESI†).
Using the phospho-RTK arrays, only tyrosine phosphoryl-
ation of ErbB3 was detected in the control MCF-7 cells (Fig. 3A).
ZIP7 overexpression resulted in an increase in EGFR tyrosine
phosphorylation and a decrease in ErbB3 tyrosine phosphoryl-
ation (Fig. 3A and 4A). The arrays confirmed zinc treatment-
induced tyrosine phosphorylation of EGFR, ErbB2, ErbB3, and
ErbB4, confirming previous data,10 and further discovered the
zinc-induced activation of ALK, EphA1, and RYK in comparison
to control MCF-7 cells (Fig. 3A and 4A). In zinc-treated cells,
wild-type ZIP7 transfection further enhanced tyrosine phos-
phorylation of ALK, EGFR, ErbB2, EphA7, and FGFR3, confirm-
ing that the activation of these kinases were influenced by ZIP7
(Fig. 3A and 4A).
The phospho-kinase arrays, enabled identification of the
phosphorylation of individual kinase residues. Multiple kinases
were already phosphorylated in control MCF-7 cells (Fig. 3B). Both
ZIP7 overexpression alone and zinc treatment alone were able to
induce phosphorylation of CREB (S133), p70 S6 (T421/S424), STAT2
(Y689), STAT5a (Y694), andWNK1 (T60) (Fig. 3B and 4B). In addition,
c-Jun (S63) was phosphorylated only by ZIP7 overexpression,
Table 1 Predicted phosphorylation sites on the loop between TM3 and
TM4 of ZIP7. Discovery of potential phosphorylation sites in ZIP7 using
PhosphoNET,20 PHOSIDA (Max Planck Institute of Biochemistry)21 and
PhosphoSitePlus.22 The underlined residue corresponds to the predicted
site. MS, mass spectrometry
Site Sequence Number of MS studies Predicted kinases
S2755 RSTKEKQSSEEEEKE 13 CK2
S2765 STKEKQSSEEEEKET 14 CK2
S293 VQKRRGGSTVPKDGP 1
23 MAPKAPK2–3
T294 QKRRGGSTVPKDGPV 1
23 PIM1–3
Fig. 2 Requirement of S275, S276, S293, and T294 for maximal ZIP7
activation. Immunoblotting using pS473 AKT and pS275/S276 ZIP7 anti-
bodies was performed in MCF-7 cells transfected with ZIP7 S275A, S276A,
S293A, and T294A mutants and treated with zinc. Representative blots (A)
and densitometric data for pS473 AKT (B) and pS275/S276 zip7 (C) are
presented. Statistical significance is compared to time 0 of each construct.
* = p o 0.05, ** = p o 0.01, and *** = p o 0.001.
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whereas AKT (S473), GSK-3a/b (S21/S9), HSP27 (S78/S82), JNK
(T183/Y185, T221/Y223), p38a MAPK (T180/Y182), STAT5a/b
(Y694/Y699), and STAT5b (Y699) were phosphorylated only by
zinc treatment alone (Fig. 3B and 4B). Cells both transfected
Fig. 3 Activation of cellular kinases by ZIP7 overexpression or zinc treatment. MCF-7 cells were transfected with or without wild-type ZIP7 and treated with or
without zinc for 10 minutes. Tyrosine phosphorylation of selected RTKs and site-specific phosphorylation of selected kinases were determined using the
phospho-RTK (A), phospho-kinase (B), and phospho-MAPK (C) antibody arrays (R&D systems). Signals for each kinase are presented as a pair of duplicate spots,
with three pairs of dark reference spots on the upper left, upper right, and lower left corners for alignment. The kinases that show any conspicuous changes in
phosphorylation (410000 density units) in the non-transfected zinc-treated cells (MCF-7 + Zn) or the transfected non-treated cells (wt-ZIP7) when compared
to the non-transfected and non-treated cells (MCF-7) are indicated. In addition, the kinases that show any conspicuous changes in phosphorylation in the
transfected zinc-treated cells (wt-ZIP7 + Zn) when compared to the non-transfected zinc-treated cells (MCF-7 + Zn) are also indicated. Average densitometric
values for these kinases are shown in bar graphs. The experiments were performed once for the phospho-RTK and phospho-MAPK arrays and twice for the
phospho-kinase arrays. Statistical significance compares wt-ZIP7 or MCF-7 + Zn to MCF-7 and wt-ZIP7 + Zn to MCF-7 + Zn. * = p o 0.05, ** = p o 0.01.
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with wild-type ZIP7 and treated with zinc had a further increase
in phosphorylation of CREB (S133), GSK-3a/b (S21/S9), HSP27
(S78/S82), p70 S6 (T421/S424), PRAS40 (T246), and WNK1 (T60)
when compared to non-transfected zinc-treated cells (Fig. 3B
and 4B), confirming ZIP7 mediation of the phosphorylation
of these kinases. Due to the high variation of the data between
the duplicates, only a small proportion of these increases were
statistically significant (Fig. 3B). Noteworthy, one of the two
replicates revealed an increase in AMPKa1 (T183) phosphorylation
by 40014 density units after zinc treatment (Fig. 3B). However, the
other replicate instead showed a decrease by 14351 density units.
This kinase was therefore not included in further studies.
To confirm the phospho-kinase array data and investigate more
MAPK isoforms, the phospho-MAPK arrays were also utilised.
Without transfection or treatment, GSK-3a/b (S21/S9), HSP27
(S78/S82), and p70 S6 (T421/S424) were already phosphorylated
(Fig. 3C). As a result of ZIP7 overexpression, GSK-3a/b (S21/S9)
and p70 S6 (T421/S424) were further phosphorylated (Fig. 3C
and 4C). Consistent with the phospho-kinase array results, zinc
treatment alone induced phosphorylation of AKT1 (S473), CREB
(S133), GSK-3a/b (S21/S9), HSP27 (S78/S82), JNK (T183/Y185,
T221/Y223) and p70 S6 (T421/S424), with additional detection
of AKT2 (S474) and ERK1 (T202/Y204) (Fig. 3C and 4C). ZIP7
transfection plus zinc treatment revealed further activation of
CREB (S133), GSK-3a/b (S21/S9), HSP27 (S78/S82), and p70 S6
(T421/S424) (Fig. 3C and 4C).
All the antibody array data together have revealed multiple
kinases phosphorylated as a direct result of ZIP7-mediated zinc
release from cellular stores, which are listed in Table 2. Inter-
estingly, there is good agreement between the kinases activated
by ZIP7 and those activated by zinc treatment. As the observed
activation of p38a MAPK by the zinc treatment may have been
indicative of an unphysiological zinc stimulation, we stimulated
further phospho-RTK and phospho-kinase arrays with EGF and
Ionomycin, which have previously been demonstrated to activate
ZIP7-mediated zinc release.5 This stimulation did not show any
RTK phosphorylation on the phospho-RTK arrays except EGFR,
which might result from the direct activation by EGF indepen-
dently of ZIP7-mediated zinc release (Fig. 5A). The phospho-kinase
arrays confirmed the ZIP7-dependent phosphorylation of CREB,
ERK1/2, p70 S6, STAT2, and WNK1, with additional increase in
the total HSP60 level observed as a result of the stimulation
(Fig. 5B). Importantly, p38a MAPK activation was not seen as a
result of this treatment, suggesting possible cell stress induced
by supra-physiologic zinc stimulation. Noteworthy, ZIP7 trans-
fection in addition to stimulation with EGF plus Ionomycin
further enhanced phosphorylation AMPKa2 (T172), CREB
(S133), p70 S6 (T421/S424), STAT2 (Y689), and STAT6 (Y641)
(Fig. 5B), confirming these kinases as downstream eﬀectors
of ZIP7.
GSK-3b and p70 S6 are key downstream eﬀectors of
ZIP7-mediated zinc release
To confirm the antibody array data, cells with and without ZIP7
transfection and/or 10 minutes of zinc treatment were probed
with various antibodies by Western blotting. Phosphorylation
of CREB (S133) (Fig. 6A), GSK-3b (S9) (Fig. 6B) and pT421/S424
Fig. 4 Cellular kinases activated by ZIP7 overexpression or zinc treatment.
MCF-7 cells were transfected with or without wild-type ZIP7 and treated
with or without zinc for 10 minutes. Tyrosine phosphorylation of selected
RTKs and site-specific phosphorylation of selected kinases were determined
using the phospho-RTK (A), phospho-kinase (B), and phospho-MAPK
(C) arrays (R&D systems). Average densitometric values are presented as
a spectrum of colour where blue and red colours represent the lowest and
the highest values in the row according to the indicated scale.
Table 2 Downstream eﬀectors of ZIP7-mediated zinc release and zinc
treatment shows the kinases phosphorylated by either wild-type ZIP7
transfection or zinc treatment from the antibody arrays. Kinases with more
than one isoform or modification are merged together. Kinases shown in
bold are phosphorylated by both ZIP7 transfection and a treatment, either
zinc plus sodium pyrithione or EGF plus ionomycin (EGF/I). Only kinases
with changes in levels by more than 10000 density units are listed
ZIP7 transfection Zinc treatment EGF/I treatment
Receptor-tyrosine kinases (RTK) arrays
ALK EphA7 ALK ErbB4 EGFR
EGFR FGFR3 EGFR EphA1
ErbB2 ErbB2 RYK
ErbB3
Phospho-kinase and mitogen-activated protein kinases (MAPK) arrays
AKT p53 AKT JNK CREB p70 S6
AMPK p70 S6 AMPK p38a ERK1/2 STAT2
c-Jun PRAS40 CREB MAPK HSP60 WNK1
CREB STAT2 GSK-3 p70 S6
ERK1/2 STAT5 a/b STAT5
GSK-3a/b STAT6 HSP27 WNK1
HSP27 WNK1
JNK
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p70 S6 (Fig. 6C) was apparently increased as a result of zinc
treatment in the transfected cells when compared to the
untreated cells, with the phospho-kinase levels being higher in
the transfected cells than the untransfected cells when treated
with zinc. In contrast, phosphorylation of p38 MAPK on
Y180/Y182 was induced only by zinc, with no diﬀerence detected
due to the ZIP7 transfection (Fig. 6D). Directly contradicting the
phospho-array data, pS392 p53 (Fig. 6E), pS726 STAT5 (Fig. 6F),
and pT60 WNK1 (Fig. 6G) did not show an apparent increase
as a result of either ZIP7 overexpression or zinc treatment.
Collectively, these results have confirmed CREB, GSK-3b and
p70 S6 as downstream eﬀectors of ZIP7-mediated zinc release
from cellular stores.
To decipher the relationship of phosphorylation of GSK-3b
on residue S9 with ZIP7 activation by phosphorylation on
residues S275/S276, a course of zinc treatment was performed
in cells transfected with either wild-type ZIP7 or the ZIP7 S276A/
S276A mutant. GSK-3b was phosphorylated on residue S9 after
10 minutes of zinc treatment in cells transfected with wild-
type ZIP7 compared to the delay of 15 minutes with the ZIP7
S275A/S276A mutant (Fig. 6H and I), confirming that this
GSK-3b phosphorylation is dependent upon ZIP7 phosphorylation
on residues S275/S276.
D Conclusions
Using diﬀerent phospho-kinase arrays, we have discovered multi-
ple kinases phosphorylated as a direct result of ZIP7-mediated zinc
release from intracellular stores (Fig. 3–5 and Table 2). Interest-
ingly, many of these kinases are linked together in an integrated
network of carcinogenesis-related pathways, involving MAPK,
PI3K-AKT, and MTOR pathways (Fig. 7). In response to an extra-
cellular stimulus, ZIP7 is activated by phosphorylation on residues
S275 and S276, resulting in zinc release from intracellular stores,5
inhibition of protein tyrosine phosphatases,6,24,25 and thereby
activation of RTKs as well as other cellular kinases,10 which may
be triggered directly by zinc or indirectly by the zinc-activated
RTKs. Here we confirm that activation of AKT is a major early
response to ZIP7 activation,5 showing a significant increase within
Fig. 5 Activation of cellular kinases by ZIP7 overexpression or EGF and ionomycin treatment. MCF-7 cells were transfected with or without wild-type ZIP7
and treated with or without EGF plus ionomycin (EGF/I) for 10 minutes. Tyrosine phosphorylation of selected RTKs and site-specific phosphorylation of
selected kinases were determined using the phospho-RTK (A) and phospho-kinase (B) antibody arrays (R&D systems). Signals for each kinase are presented
as a pair of duplicate spots, with three pairs of dark reference spots on the upper left, upper right, and lower left corners for alignment. The kinases that
show any changes in phosphorylation (410000 density units) in the non-transfected EGF/I-treated cells (MCF-7 + EGF/I) when compared to the non-
transfected and non-treated cells (MCF-7), or in the transfected EGF/I-treated (wt-ZIP7 + EGF/I) when compared to the non-transfected EGF/I-treated
cells (MCF-7 + EGF/I) are indicated. Average densitometric values for these kinases are shown in bar graphs. The experiments were performed once.
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5 minutes of a treatment (Fig. 1B) that stimulated phosphorylation
of ZIP7 within 2 minutes (Fig. 1D). Interestingly, the observed
inhibition of GSK-3b was not significant until 10 minutes after
stimulation (Fig. 6H and I), suggesting that it may have been
reliant on preceding AKT activation.26 However, zinc has been
shown to be able to inhibit GSK-3b directly by triggering
phosphorylation of it on residue S9.27
The activation of AKT is known to result from the inhibitory
eﬀect of zinc on protein tyrosine phosphatases24 or indirectly
from zinc-induced phosphorylation of RTKs such as IGF-1R.27
Importantly, silencing protein tyrosine phosphatase 1B, a notable
zinc-modulated phosphatase25 which is involved in EGFR, IGF-1R
and Src signalling,10 also enhances AKT phosphorylation.28 We
therefore propose that the ZIP7-mediated release of zinc from
intracellular stores is suﬃcient to activate multiple signalling
pathways involved in encouraging growth and proliferation,
especially those known to be aberrantly activated in diseases
such as cancer.29–31
Using the phospho-arrays, we also discovered that CREB and
p70 S6 kinases were both consistently activated by ZIP7-mediated
zinc release (Fig. 3 and 4) which was amplified further by zinc
(Fig. 4). Both CREB and p70 S6 kinase are known to be phos-
phorylated in response to zinc using the ERK1/232 and the EGF-
dependent PI3K pathways,33 respectively. In neuroblastoma cells,
zinc-induced phosphorylation of p70 S6 kinase is associated with
the pathogenesis of Alzheimer’s disease,34 and in pancreatic
cancer cells, ZIP4 overexpression results in CREB phosphoryl-
ation, which in turn induces cyclin D1 expression and thereby
cell proliferation.35 Importantly, phosphorylation of CREB,36
GSK-3b,37 and p70 S638 have all been shown to contribute to cell
proliferation and survival, linking ZIP7 to these major signalling
pathways.
ZIP7, a gatekeeper for zinc release from cellular stores and a
hub for phosphorylation of tyrosine kinases,18 actively participates
in carcinogenesis,15 including but not limited to the develop-
ment of endocrine resistance in breast cancer.10 Furthermore,
Fig. 6 Investigation of ZIP7-dependent phosphorylation of GSK-3b, CREB, p38 MAPK, p53, p70 S6, STAT5 and WNK1. Immunoblotting using pS133
CREB (A), pS9 GSK-3b (B), pT421/S424 p70 S6 (C), pY180/Y182 p38 MAPK (D), pS392 p53 (E), pS726 STAT5 (F), and pT60 WNK1 (G) antibodies was
performed in MCF-7 cells transfected with and without wild-type ZIP7 and treated with zinc for 0–10 minutes. Immunoblotting using the pS9 GSK-3b
antibody was also performed onMCF-7 cells transfected with wild-type ZIP7 and the ZIP7 S275A/S276Amutant and treated with zinc for 0–15minutes (H and I).
Statistical significance is compared to time 0. * = p o 0.05.
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using Kaplan–Meier analysis, we have previously reported that
high ZIP7 gene expression is associated with decreased relapse-
free survival in breast cancer patients when compared to
low ZIP7 expression cases.39 These findings therefore will
help us to understand the consequences of action of ZIP7 in
order to develop a novel strategy for targeting ZIP7 in cancer
patients.
We have developed a monoclonal antibody and demon-
strated that it specifically recognises the active form of ZIP7.
Interestingly, this antibody produced an 8-kDa mobility shift
compared to total ZIP7 (Fig. 1A), consistent with the presence of
additional phosphorylated residues in ZIP7.40 Furthermore, our
investigation into the phosphorylation of residues S293 and
T294 in ZIP7 is consistent with the presence of hierarchical
phosphorylation,41 a common feature of CK2 phosphorylation
patterns.42 We determined that all four residues, S275, S276,
S293, and T294 in ZIP7 were required for full activation of ZIP7-
mediated zinc release (Fig. 2), suggesting a complexity yet to be
deciphered. The development of the pZIP7 antibody now pro-
vides a useful tool for assessing the activation state of zinc
signalling in cells, particularly a measure of the activation of
the multiple signalling pathways downstream of ZIP7-mediated
zinc release, such as AKT, PI3K, MAPK and MTOR. Additionally,
as there is currently no reliable biomarker for total body zinc
status assessment,43 and ZIP7 is ubiquitously expressed, espe-
cially in immune cells, this pZIP7 antibody should be investigated
for eﬃcacy in this area as a reliable biomarker of zinc status to
benefit those with zinc deficiency.
Acknowledgements
This work was supported by a Wellcome Trust University
Research Award [grant number 091991/Z/10/Z]. SZ is supported
by Tenovus Cancer Care [grant number PhD2015/L31]. TN, SZ,
and KMT are members of the European COST action ZINC-NET.
TN is funded by the Royal Thai Government.
Notes and references
1 H. Haase and L. Rink, Zinc signals and immune function,
BioFactors, 2014, 40(1), 27–40.
2 W. Maret, Metallothionein redox biology in the cytoprotective
and cytotoxic functions of zinc, Exp. Gerontol., 2008, 43(5),
363–369. Epub 2008/01/04.
3 A. R. Kay and K. To´th, Is zinc a neuromodulator?, Sci.
Signaling, 2008, 1(19), re3.
4 S. Yamasaki, K. Sakata-Sogawa, A. Hasegawa, T. Suzuki, K. Kabu
and E. Sato, et al., Zinc is a novel intracellular secondmessenger,
J. Cell Biol., 2007, 177(4), 637–645. Epub 2007/05/16.
5 K. M. Taylor, S. Hiscox, R. I. Nicholson, C. Hogstrand and
P. Kille, Protein kinase CK2 triggers cytosolic zinc signaling
pathways by phosphorylation of zinc channel ZIP7, Sci.
Signaling, 2012, 5(210), ra11.
6 M. Wilson, C. Hogstrand and W. Maret, Picomolar concen-
trations of free zinc(II) ions regulate receptor protein-tyrosine
phosphatase b activity, J. Biol. Chem., 2012, 287(12),
9322–9326.
7 L. A. Lichten and R. J. Cousins, Mammalian zinc trans-
porters: nutritional and physiologic regulation, Annu. Rev.
Nutr., 2009, 29, 153–176.
8 T. Kambe, T. Tsuji, A. Hashimoto and N. Itsumura, The
Physiological, Biochemical, and Molecular Roles of Zinc
Transporters in Zinc Homeostasis and Metabolism, Physiol.
Rev., 2015, 95(3), 749–784. Epub 2015/06/19.
9 K. M. Taylor, H. E. Morgan, K. Smart, N. M. Zahari,
S. Pumford and I. O. Ellis, et al., The emerging role of the
Fig. 7 Schematic of ZIP7-mediated activation pathways. This schematic demonstrates carcinogenesis-related pathways that are activated downstream
of ZIP7-mediated zinc release as observed from the phospho-array data (white box), showing activation of MAPK, PI3K-AKT, and mTOR pathways.
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
8 
Fe
br
ua
ry
 2
01
7.
 D
ow
nl
oa
de
d 
on
 3
0/
05
/2
01
7 
17
:3
7:
05
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
480 | Metallomics, 2017, 9, 471--481 This journal is©The Royal Society of Chemistry 2017
LIV-1 subfamily of zinc transporters in breast cancer, Mol.
Med., 2007, 13(7-8), 396–406.
10 K. M. Taylor, P. Vichova, N. Jordan, S. Hiscox, R. Hendley
and R. I. Nicholson, ZIP7-mediated intracellular zinc trans-
port contributes to aberrant growth factor signaling in
antihormone-resistant breast cancer Cells, Endocrinology,
2008, 149(10), 4912–4920.
11 J. M. Knowlden, I. R. Hutcheson, H. E. Jones, T. Madden,
J. M. Gee and M. E. Harper, et al., Elevated levels of
epidermal growth factor receptor/c-erbB2 heterodimers
mediate an autocrine growth regulatory pathway in tamoxifen-
resistant MCF-7 cells, Endocrinology, 2003, 144(3), 1032–1044.
Epub 2003/02/15.
12 H. E. Jones, L. Goddard, J. M. Gee, S. Hiscox, M. Rubini and
D. Barrow, et al., Insulin-like growth factor-I receptor sig-
nalling and acquired resistance to gefitinib (ZD1839; Iressa)
in human breast and prostate cancer cells, Endocr.-Relat.
Cancer, 2004, 11(4), 793–814.
13 S. Hiscox, L. Morgan, T. P. Green, D. Barrow, J. Gee and
R. I. Nicholson, Elevated Src activity promotes cellular
invasion and motility in tamoxifen resistant breast cancer
cells, Breast Cancer Res. Treat., 2006, 97(3), 263–274.
14 A. Bourdeau, N. Dube and M. L. Tremblay, Cytoplasmic
protein tyrosine phosphatases, regulation and function: the
roles of PTP1B and TC-PTP, Curr. Opin. Cell Biol., 2005,
17(2), 203–209.
15 T. Nimmanon and K. M. Taylor, Zinc signalling and cancer.
in Zinc Signals in Cellular Functions and Disorders, ed.
T. Fukada and T. Kambe, Springer Japan, Tokyo, 2014,
pp. 285–313.
16 K. M. Taylor, H. E. Morgan, A. Johnson and R. I. Nicholson,
Structure-function analysis of HKE4, a member of the new
LIV-1 subfamily of zinc transporters, Biochem. J., 2004,
377(Pt 1), 131–139.
17 R. A. Valentine, K. A. Jackson, G. R. Christie, J. C. Mathers,
P. M. Taylor and D. Ford, ZnT5 variant B is a bidirectional
zinc transporter and mediates zinc uptake in human intest-
inal Caco-2 cells, J. Biol. Chem., 2007, 282(19), 14389–14393.
18 C. Hogstrand, P. Kille, R. I. Nicholson and K. M. Taylor, Zinc
transporters and cancer: a potential role for ZIP7 as a hub
for tyrosine kinase activation, Trends Mol. Med., 2009, 15(3),
101–111.
19 K. M. Taylor, H. E. Morgan, A. Johnson, L. J. Hadley and
R. I. Nicholson, Structure-function analysis of LIV-1, the breast
cancer-associated protein that belongs to a new subfamily of
zinc transporters, Biochem. J., 2003, 375(Pt 1), 51–59.
20 J. V. Olsen, M. Vermeulen, A. Santamaria, C. Kumar,
M. L. Miller and L. J. Jensen, et al., Quantitative phospho-
proteomics reveals widespread full phosphorylation site
occupancy during mitosis, Sci. Signaling, 2010, 3(104), ra3.
21 Kinexus Bioinformatics Corporation, PhosphoNET: Human
Phospho-Site KnowledgeBase, available from: http://www.
phosphonet.ca.
22 F. Gnad, J. Gunawardena and M. Mann, PHOSIDA 2011: the
posttranslational modification database, Nucleic Acids Res.,
2011, 39(Database issue), D253–D260.
23 P. V. Hornbeck, B. Zhang, B. Murray, J. M. Kornhauser,
V. Latham and E. Skrzypek, PhosphoSitePlus, 2014: muta-
tions, PTMs and recalibrations, Nucleic Acids Res., 2015,
43(database issue), D512–D520.
24 H. Haase and W. Maret, Protein tyrosine phosphatases as
targets of the combined insulinomimetic eﬀects of zinc and
oxidants, BioMetals, 2005, 18(4), 333–338.
25 E. Bellomo, A. Massarotti, C. Hogstrand and W. Maret, Zinc
ions modulate protein tyrosine phosphatase 1B activity,
Metallomics, 2014, 6(7), 1229–1239.
26 S. F. Moore, M. T. van den Bosch, R. W. Hunter, K. Sakamoto,
A. W. Poole and I. Hers, Dual regulation of glycogen synthase
kinase 3 (GSK3)a/b by protein kinase C (PKC)a and Akt pro-
motes thrombin-mediated integrin aIIbb3 activation and
granule secretion in platelets, J. Biol. Chem., 2013, 288(6),
3918–3928.
27 S. Lee, G. Chanoit, R. McIntosh, D. A. Zvara and Z. Xu,
Molecular mechanism underlying Akt activation in zinc-
induced cardioprotection, Am. J. Physiol.: Heart Circ. Physiol.,
2009, 297(2), H569–H575.
28 P. G. Trave´s, V. Pardo, M. Pimentel-Santillana, A´. Gonza´lez-
Rodrı´guez, M. Mojena and D. Rico, et al., Pivotal role of
protein tyrosine phosphatase 1B (PTP1B) in the macrophage
response to pro-inflammatory and anti-inflammatory
challenge, Cell Death Dis., 2014, 5, e1125.
29 H. Po´pulo, J. M. Lopes and P. Soares, The mTOR signalling
pathway in human cancer, Int. J. Mol. Sci., 2012, 13(2),
1886–1918.
30 A. S. Dhillon, S. Hagan, O. Rath and W. Kolch, MAP kinase
signalling pathways in cancer, Oncogene, 2007, 26(22),
3279–3290.
31 P. Liu, H. Cheng, T. M. Roberts and J. J. Zhao, Targeting the
phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug
Discovery, 2009, 8(8), 627–644.
32 J. R. Nuttall and P. I. Oteiza, Zinc and the ERK kinases in the
developing brain, Neurotoxic Res., 2012, 21(1), 128–141.
33 S. Kim, Y. Jung, D. Kim, H. Koh and J. Chung, Extracellular
zinc activates p70 S6 kinase through the phosphatidylinositol
3-kinase signaling pathway, J. Biol. Chem., 2000, 275(34),
25979–25984.
34 W. L. An, C. Bjorkdahl, R. Liu, R. F. Cowburn, B. Winblad
and J. J. Pei, Mechanism of zinc-induced phosphorylation
of p70 S6 kinase and glycogen synthase kinase 3beta in
SH-SY5Y neuroblastoma cells, J. Neurochem., 2005, 92(5),
1104–1115.
35 Y. Zhang, U. Bharadwaj, C. D. Logsdon, C. Chen, Q. Yao and
M. Li, ZIP4 regulates pancreatic cancer cell growth by
activating IL-6/STAT3 pathway through zinc finger transcrip-
tion factor CREB, Clin. Cancer Res., 2010, 16(5), 1423–1430.
36 K. M. Sakamoto and D. A. Frank, CREB in the pathophysiology
of cancer: implications for targeting transcription factors for
cancer therapy, Clin. Cancer Res., 2009, 15(8), 2583–2587.
37 M. Soda, K. Willert, K. Kaushansky and A. E. Geddis, Inhibi-
tion of GSK-3beta promotes survival and proliferation of
megakaryocytic cells through a beta-catenin-independent
pathway, Cell Signalling, 2008, 20(12), 2317–2323.
Paper Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
8 
Fe
br
ua
ry
 2
01
7.
 D
ow
nl
oa
de
d 
on
 3
0/
05
/2
01
7 
17
:3
7:
05
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2017 Metallomics, 2017, 9, 471--481 | 481
38 M. Piedfer, S. Bouchet, R. P. Tang, C. Billard, D. Dauzonne
and B. Bauvois, p70S6 kinase is a target of the novel
proteasome inhibitor 3,30-diamino-40-methoxyflavone during
apoptosis in human myeloid tumor cells, BBA, Biochim.
Biophys. Acta, Mol. Cell Res., 2013, 1833(6), 1316–1328.
39 T. Nimmanon and K. M. Taylor, Cellular Zinc Signalling Is
Triggered by CK2, in Protein Kinase CK2 Cellular Function in
Normal and Disease States, ed. K. Ahmed, O.-G. Issinger and
R. Szyszka, Springer International Publishing, Switzerland,
2015, pp. 141–157.
40 B. H. Bin, T. Fukada, T. Hosaka, S. Yamasaki, W. Ohashi
and S. Hojyo, et al., Biochemical characterization of human
ZIP13 protein: a homo-dimerized zinc transporter involved
in the spondylocheiro dysplastic Ehlers-Danlos syndrome,
J. Biol. Chem., 2011, 286(46), 40255–40265.
41 H. Lodish, A. Berk, S. L. Zipursky, P. Matsudaira, D. Baltimore
and J. Darnell,Hierarchical Structure of Proteins, W. H. Freeman,
New York, 4th edn, 2000, available from: http://www.ncbi.nlm.
nih.gov/books/NBK21581.
42 N. St-Denis, M. Gabriel, J. P. Turowec, G. B. Gloor, S. S. Li and
A. C. Gingras, et al., Systematic investigation of hierarchical
phosphorylation by protein kinase CK2, J. Proteomics, 2015,
118, 49–62.
43 F. T. Wieringa, M. A. Dijkhuizen, M. Fiorentino, A. Laillou and
J. Berger, Determination of zinc status in humans: which
indicator should we use?, Nutrients, 2015, 7(5), 3252–3263.
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
8 
Fe
br
ua
ry
 2
01
7.
 D
ow
nl
oa
de
d 
on
 3
0/
05
/2
01
7 
17
:3
7:
05
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
